country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-149231

Copy Link Print Information

Anticancer agent 104

Anticancer agent 104 has anticancer activity, and induces cancer cell apoptosis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 3047612-51-8
分子式: C₃₄H₄₇F₃N₂O₂S₂
分子量:636.87

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (274 KB)

Anticancer agent 104 構造式

CAS 番号: 3047612-51-8

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Anticancer agent 104 has anticancer activity, and induces cancer cell apoptosis^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	91.67 μM Compound: 4l	Anticancer activity against human 786-0 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human 786-0 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37084600]
Calu-1	IC₅₀	78.34 μM Compound: 4l	Anticancer activity against human Calu-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human Calu-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37084600]
HEK-293T	IC₅₀	195.17 μM Compound: 4l	Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37084600]
HepG2	IC₅₀	31.39 μM Compound: 4l	Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37084600]
Huh-7	IC₅₀	75.18 μM Compound: 4l	Anticancer activity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37084600]
KGN	IC₅₀	176.38 μM Compound: 4l	Cytotoxicity against human KGN cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human KGN cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37084600]
LX-2	IC₅₀	96.33 μM Compound: 4l	Cytotoxicity against human LX2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human LX2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37084600]
MCF-10A	IC₅₀	21.06 μM Compound: 4l	Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37084600]
SK-BR-3	IC₅₀	44.18 μM Compound: 4l	Anticancer activity against human SK-BR-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human SK-BR-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37084600]
SK-OV-3	IC₅₀	112.19 μM Compound: 4l	Anticancer activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37084600]
WI-38	IC₅₀	81.48 μM Compound: 4l	Cytotoxicity against human WI-38 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37084600]

体外実験

Anticancer agent 104 (Compound 4l) (48 h) is toxic to HepG2 cells (IC₅₀: 31.39 μM)^[1].
Anticancer agent 104 (10-200 μg/mL, 48 h) exhibits volume reduction, chromatin margination, and eventually formed apoptotic vesicles^[1].
Anticancer agent 104 (10-100 μg/mL, 48 h) induces HepG2 cell apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

Calu-1, SK-BR-3, HUH-7, 786-O, SK-OV-3 cells
Concentration:

0-200 μM approximately
Incubation Time:

48 h
Result:

Shows cytotoxic activities with IC₅₀s of 78.34, 44.18, 75.18, 91.67, 112.19 μM.

Apoptosis Analysis^[1]

Cell Line:

HepG2 cells
Concentration:

10, 50 and 100 μg/mL
Incubation Time:

48 h
Result:

Showed apoptotic rate of 23.67%, 41.21% and 61.16% respectively.

Related Protocols :

化学情報

CAS 番号 3047612-51-8
分子量 636.87
分子式 C₃₄H₄₇F₃N₂O₂S₂
SMILES

C[C@@]1(C(C)([C@@](CC1)([H])C2)C)[C@@H]2OC(CCC[C@@H]3[C@]4([H])[C@]5([H])[C@](CCCN5CCC4)([H])CN3C(SCC6=CC=C(C=C6)C(F)(F)F)=S)=O
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (274 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Zhang MW, et al. Design, synthesis and biological evaluation of matrine-dithiocarbamate hybrids as potential anticancer agents. Eur J Med Chem. 2023 Jun 5;254:115375. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ